EurekaMag
+ Translate
+ Most Popular
Sobre os generos Lopadusa Stal e Bothrocoris Mayr (Hemiptera, Pentatomidae, Pentatomini)
RFEF pilot plant for inactivation of Escherichia coli in apple juice
Calpionella alpina Lorenz als "Leitfossil"
Sooretama: The Atlantic Rain Forest of Brazil. Francis Dov Por
Novel approaches in myeloma therapy
Preliminary Notes on the Study of Mitochondria During the 1st Stages of the Destruction of Cadavers
A preliminary study of the biology of lichee stink bug, Tessaratoma papulosa Drury, and its control
The status of the Sabu Island python - Die Situation des Savu-Pythons
Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. the UK Group for Immunoglobulin Replacement therapy in Multiple Myeloma
Conflicts between children
Clinical presentations in neuropsychiatry
Method of suturing a perforated ulcer of the stomach and duodenum
Identification of mechanical asphyxiation in cases of attempted masking of the homicide
Effects of endogenous ascorbate on oxidation, oxygenation, and toxicokinetics of cell-free modified hemoglobin after exchange transfusion in rat and guinea pig
Is it warm? Is it real? Or just low spatial frequency?
Additions and corrections to the list of Korean Heteroptera
Factors contributing to the maintenance of oligotrophy in an alpine glacial moraine lake (Wallowa lake) in Northeast Oregon
Classification, paleoecology, and biostratigraphy of crinoids from the Stull Shale (Late Pennsylvanian) of Nebraska, Kansas, and Iowa
Observations of the propagation velocity and formation mechanism of burst fractures caused by gunshot
Neue Formen der Bauchsammler aus Turkmenien (Hymenoptera, Apoidea)
Atypische Hühnerpest und Newcastle-Krankheit. Ein Identifizierungsversuch
Parasitellus fucorum in the debris of Apis mellifera - a risk of confusion with Tropilaelaps spp
Applying the Technology Acceptance Model to the introduction of healthcare information systems
Ein akarologischer Nachruf für den "Roland"
Mutation research on crop plants in Argentina

GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6


GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6



Haematologica 100(3): 377-384



ISSN/ISBN: 0390-6078

PMID: 25637055

DOI: 10.3324/haematol.2014.117945

The primary objective of this phase 1 study was to evaluate the safety and tolerability of the anti-glucose regulated protein 78 monoclonal immunoglobulin M antibody PAT-SM6 in subjects with relapsed or refractory multiple myeloma. Twelve heavily pretreated patients received four intravenous infusions of PAT-SM6 at doses of 0.3, 1, 3, and 6 mg/kg within 2 weeks. Efficacy, pharmacokinetics and immunogenicity were followed up until the end of the trial (day 36). In addition, immune cell patterns in peripheral blood were assessed by flow cytometry and glucose regulated protein 78 expression status was evaluated in bone marrow specimens by immunohistochemistry and flow cytometry at screening. All doses administered were found to be safe and well tolerated; the maximum tolerated dose was not reached. The most common treatment emergent adverse event was leukopenia (grades 1 and 2) in eight out of the 12 multiple myeloma patients. Pharmacokinetic analysis demonstrated dose-proportional increases in drug serum concentration. The terminal half-life ranged from 5.86 to 8.41 h, the apparent volume of distribution ranged from 101 to 150 mL/kg, and clearance ranged from 8.11 to 16.1 mL/h/kg. All patients showed glucose regulated protein 78 surface expression on multiple myeloma cells. Four out of the 12 patients (33.3 %) had stable disease, according to the International Myeloma Working Group criteria, after PAT-SM6 treatment across the doses 1, 3 and 6 mg/kg. In summary, single-agent PAT-SM6 was well tolerated with modest clinical activity in relapsed or refractory multiple myeloma. Further trials exploring the combination of PAT-SM6 with existing myeloma therapies are planned. clinicaltrials.gov identifier: NCT01727778.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057915935

Download citation: RISBibTeXText

Related references

Phase i trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 30(16): 1960-1965, 2012

MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial. Lancet. Haematology 7(5): E381-E394, 2020

Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma. British Journal of Haematology 163(4): 478-486, 2013

Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results. British Journal of Haematology 180(6): 821-830, 2018

Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma. International Journal of Hematology 101(3): 286-294, 2015

A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood 120(22): 4324-4333, 2012

A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. British Journal of Haematology 161(3): 357-366, 2013

A Phase i Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 21(18): 4055-4061, 2015

Phase II trial of temsirolimus (CCI-779) in patients with relapsed or refractory multiple myeloma (MM): Preliminary results. Journal of Clinical Oncology 24(18_Suppl): 7616-7616, 2016

Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial. Cancer 106(6): 1316-1319, 2006

A phase 1 study of lucatumumab, a fully human anti-CD4 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. 2012

A092 Rmpt in Relapsed/Refractory Multiple Myeloma: Results of a Multicenter Phase Ii Clinical Trial. Clinical Lymphoma and Myeloma 9: S14-S15, 2009

A multicenter phase i study of inebilizumab, a humanized anti-CD19 monoclonal antibody, in Japanese patients with relapsed or refractory B-cell lymphoma and multiple myeloma. International Journal of Hematology 109(6): 657-664, 2019

A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. British Journal of Haematology 159(1): 58-66, 2012

Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/Ii trial. Haematologica 95(7): 1144-1149, 2010